NanoViricides (NNVC) announced that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an Orphan Drug Designation, ODD, by the US FDA Office of Orphan Products Development, OOPD.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC:
- NanoViricides measles virus treatment granted FDA orphan status
- NanoViricides says NV-387 can help control spread of measles
- NanoViricides files application for RPDD for NV-387 with U.S. OPDD
- NanoViricides plans to commence Phase II trial of NV-387 for Monkeypox
- NanoViricides completes manufacture of NV-387 oral gummies